Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK9 | P50750 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
| ▸ | JAK2 | O60674 | 1/20 | 0.30 |
| ▸ | JAK1 | P23458 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29628212 | 0.86 | KMT2A (0.38) | CDK9LMNAKMT2ANPC1ALDH1A1 | |
| SCHEMBL22214268 | 0.86 | KMT2A (0.38) | CDK9LMNAKMT2ANPC1ALDH1A1 | |
| SCHEMBL30728859 | 0.86 | KMT2A (0.38) | CDK9LMNAKMT2ANPC1ALDH1A1 | |
| SCHEMBL23484791 | 0.86 | — | — | |
| SCHEMBL22313520 | 0.83 | — | — | |
| SCHEMBL22205448 | 0.76 | POLB (0.34) | LMNAKMT2AALDH1A1MAPTHTT | |
| SCHEMBL20705026 | 0.76 | POLB (0.34) | LMNAKMT2AALDH1A1MAPTHTT | |
| SCHEMBL22205449 | 0.76 | POLB (0.34) | LMNAKMT2AALDH1A1MAPTHTT | |
| SCHEMBL23397596 | 0.76 | POLB (0.34) | LMNAKMT2AALDH1A1MAPTHTT | |
| SCHEMBL22205446 | 0.76 | POLB (0.34) | LMNAKMT2AALDH1A1MAPTHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220403383-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | SKYHAWK THERAPEUTICS, INC. | 2022-12-22 | — | — | US | disclosed |
| US-11091475-B2 | Methods and compositions for modulating splicing | SKYHAWK THERAPEUTICS, INC. (US) | 2021-08-17 | — | — | US | disclosed |
| US-20210171519-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | SKYHAWK THERAPEUTICS, INC. | 2021-06-10 | — | — | US | disclosed |
| US-11021708-B2 | Methods and compositions for modulating splicing | SKYHAWK THERAPEUTICS, INC. (US) | 2021-06-01 | — | — | US | disclosed |
| US-20200224199-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | SKYHAWK THERAPEUTICS, INC. | 2020-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11021708-B2 | Methods and compositions for modulating splicing | RBM17, SF3B1, SNRPA1 | CDK9 1413/4885LMNA 218/4885KMT2A 2256/4885 |
| US-20210171519-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | RBM17, SF3B1, SNRPA1 | CDK9 1413/4885LMNA 218/4885KMT2A 2256/4885 |
| US-20220403383-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | RBM17, SF3B1, SNRPA1 | CDK9 1413/4885LMNA 218/4885KMT2A 2256/4885 |
| US-11091475-B2 | Methods and compositions for modulating splicing | RBM17, SF3B1, SNRPA1 | CDK9 1413/4885LMNA 218/4885KMT2A 2256/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.